507970672 06/21/2023

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT8017810

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
TOMAS CIHLAR	05/24/2021

RECEIVING PARTY DATA

Name:	GILEAD SCIENCES, INC.	
Street Address:	333 LAKESIDE DRIVE	
City:	FOSTER CITY	
State/Country:	CALIFORNIA	
Postal Code:	94404	

PROPERTY NUMBERS Total: 1

Property Type	Number	
Application Number:	18128850	

CORRESPONDENCE DATA

Fax Number: (650)522-5575

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6505743000

Email: shannon.wong19@gilead.com
Correspondent Name: GILEAD SCIENCES, INC.
Address Line 1: 333 LAKESIDE DRIVE

Address Line 4: FOSTER CITY, CALIFORNIA 94404

ATTORNEY DOCKET NUMBER:	1343-US-NP-TK2
NAME OF SUBMITTER:	SHANNON WONG
SIGNATURE:	/Shannon Wong/
DATE SIGNED:	06/21/2023

Total Attachments: 3

source=1343-US-NP-TK2 Executed Assignment#page1.tif source=1343-US-NP-TK2 Executed Assignment#page2.tif source=1343-US-NP-TK2 Executed Assignment#page3.tif

PATENT 507970672 REEL: 064012 FRAME: 0440

ASSIGNMENT BY INVENTOR

THIS ASSIGNMENT, made by Tomas Cihlar (hereinafter referred to as Assignor), who resides at or has a mailing address at c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404;

WHEREAS, Assignor has invented certain new and useful improvements in REMDESIVIR TREATMENT METHODS, set forth in a Patent application for Letters Patent of the United States, for which Assignors have filed an application for patent both under the Patent Cooperation Treaty (PCT) and in the United States of America concurrently herewith. Where this Assignment is not filed concurrently with the application, the following identifying information may be added after execution:

U.S.	Serial No.:	17/333,389	_Filing Date:	May 28, 2021
РСТ	Serial No.:	PCT/US2021/034764	_Filing Date:	May 28, 2021

WHEREAS, Gilead Sciences, Inc., a Corporation organized under and pursuant to the laws of Delaware having its principal place of business at 333 Lakeside Drive; Foster City, California 94404 (hereinafter referred to as Assignee), is desirous of acquiring the entire right, title and interest in and to said inventions and said Application for Letters Patent of the United States, and in and to any Letters Patent of the United States to be obtained therefore and thereon.

NOW, THEREFORE, to all whom it may concern, be it known that for good and sufficient consideration, the receipt of which is hereby acknowledged, Assignor has sold, assigned, transferred and set over, and by these presents does sell, assign, transfer and set over, unto Assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions and applications for Letters Patent, and in and to any and all direct and indirect provisionals, national stage applications, divisions, continuations, continuations-in-part, substitutions, and reissues of said application, and any and all Letters Patent in the United States and all foreign countries which may be granted therefore and thereon.

1343-US-NP-WO-PCT

and reissues, reexaminations and extensions of said Letters Patent, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee, for its own use and benefit and the use and benefit of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent may be granted and/or extended, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

AND for the same consideration, Assignor hereby represents and warrants to Assignee, its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, except for any rights, titles and/or interests that have arisen to Assignee under law or that have already been transferred to Assignee, Assignor is the sole and lawful owner of the entire right, title and interest in and to the said inventions and application for Letters Patent above-mentioned, and that the same are unencumbered and that Assignor has good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, Assignor hereby covenants and agrees to and with Assignee, its successors, legal representatives and assigns, that Assignor will sign all papers and documents, take all lawful oaths and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of any Letters Patent and applications for Letters Patent for said inventions, without charge to Assignee, its successors, legal representatives and assigns, whenever counsel of Assignee, or counsel of its successors, legal representatives and assigns, shall advise: that any proceeding in connection with said inventions, or said Patent application for Letters Patent, or any proceeding in connection with any Letters Patent or applications for Letters Patent for said inventions including but not limited to interference proceedings, is lawful and desirable; or, that any division, continuation or continuation-in-part of any application for Letters Patent, or any reissue, reexamination or extension of any Letters Patent, to be obtained thereon, is lawful and desirable.

AND Assignor acknowledges an obligation of assignment of this invention to Assignee at the time the invention was made.

1348-US-NP-WO-PCT

I hereby grant Assignee(s), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

Date: 5/24/2021 Signature: Tomas Cihler

TOAGUS-MPUMOLACT